An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Olaratumab (Primary) ; Pembrolizumab (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Eli Lilly
- 20 Oct 2017 Planned End Date changed from 13 Feb 2020 to 1 Jun 2020.
- 20 Oct 2017 Planned primary completion date changed from 19 Mar 2019 to 1 Jun 2019.
- 07 Jul 2017 Status changed from not yet recruiting to recruiting.